Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	76.01T
Revenue (ttm)	4.55T
Net Income (ttm)	1.08T
Shares Out	71.17M
EPS (ttm)	15,220.67
PE Ratio	70.17
Forward PE	60.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,288
Average Volume	67,080
Open	1,066,000
Previous Close	1,083,000
Day's Range	1,059,000 - 1,080,000
52-Week Range	721,000 - 1,209,000
Beta	0.34
RSI	41.20
Earnings Date	Apr 23, 2025

About Samsung Biologics

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality ass...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,744
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2024, Samsung Biologics's revenue was 4.55 trillion, an increase of 23.08% compared to the previous year's 3.69 trillion. Earnings were 1.08 trillion, an increase of 26.31%.